Barinthus Biotherapeutics plc.
BRNS.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing novel T cell immunotherapeutic platforms designed to treat chronic infectious diseases, autoimmune diseases, and cancer. The company's lead product candidate is VTP-1522, a Phase 2b ready therapeutic vac...Show More
Better Health for All
40
The company's entire business is devoted to developing immunotherapies for serious diseases such as celiac disease, chronic Hepatitis B (HBV), and prostate cancer, which affect millions globally and have significant unmet needs.
1
All pipeline products are designed to provide substantial health benefits, with no evidence of harmful products or revenue. Preliminary safety data for VTP-1000 and VTP-300 clinical trials show no treatment-related serious adverse events (SAEs) among the 18 and 121 participants, respectively.
2
As a clinical-stage biopharmaceutical company, its core activity is the development of novel immunotherapeutic candidates, indicating 100% investment in health innovation.
3
VTP-1000 aims to restore immune tolerance to gluten, and VTP-300 is a potential functional cure for HBV, both representing preventative or curative approaches.
4
The company conducts randomized, placebo-controlled clinical trials (e.g., AVALON trial NCT06310291, HBV003 trial NCT05343481) with specified participant numbers and inclusion criteria, and registers its trials.
5
Fair Money & Economic Opportunity
0
No evidence available to assess Barinthus Biotherapeutics plc on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
10
Barinthus Biotherapeutics plc has an overall employee rating of 4.1 out of 5 stars, which translates to an employee satisfaction index of 82%.
1
Additionally, 81% of employees would recommend working at the company, and 72% approve of the CEO.
2
The company's culture and values, and diversity, equity & inclusion both received a rating of 4.5 out of 5.
3
Work/life balance was rated 4.5 out of 5, senior management 3.7 out of 5, and compensation and benefits 3.8 out of 5.
4
Employee concerns about low pay and poor promotion structure have been noted, and the overall employee rating decreased by 5% over 12 months.
5
No specific regulatory actions, violations, fines, or compliance issues related to labor laws or human rights are mentioned in the provided articles.
6
Fair Trade & Ethical Sourcing
0
No evidence was found in the provided articles to assess Barinthus Biotherapeutics plc against any of the Fair Trade & Ethical Sourcing KPIs. The articles primarily discuss company updates, financial results, pipeline developments, or were inaccessible/irrelevant.
1
Honest & Fair Business
0
No evidence available to assess Barinthus Biotherapeutics plc on Honest & Fair Business.
Kind to Animals
-40
Barinthus Biotherapeutics plc uses *in vitro* testing, AI-driven modeling tools, and "leukemia-on-a-chip" technology as alternative testing methods.
1
The 3Rs principle (Replacement, Reduction, and Refinement) influences the selection of viral vectors to reduce the burden on animal subjects.
2
The company mentions compliance with requirements for the humane use of laboratory animals.
3
Its animal testing policy includes animal studies to assess the safety and activity of product candidates, operating within a regulatory environment where bodies like NIH, EMA, and FDA have introduced stringent guidelines for the use of non-human primates (NHPs) and viral vectors, including detailed protocols for animal welfare.
4
The company engages in cross-disciplinary collaborations between neuroscientists, virologists, and bioengineers to innovate vector design.
5
Its Cell and Gene Therapy (CGT)- TRACS Committee's Annual Business Meeting was held virtually.
6
The company's public policy engagement includes attending events like the American College of Toxicology Annual Meeting and the World Water Congress, and its TEA Committee hosted a regional symposium on agrochemical safety evaluation in South America, convening over 20 regulatory scientists from 9 Latin American countries.
7
No War, No Weapons
0
No evidence available to assess Barinthus Biotherapeutics plc on No War, No Weapons.
Planet-Friendly Business
0
No specific, concrete data points were found in the provided articles to assess Barinthus Biotherapeutics plc against the 'Planet-Friendly Business' ethical value. While the company reported Scope 1 and 2 emissions for 2022 (113.22 tCO₂e) and 2023 (366.54 tCO₂e),
1
these figures are significantly below the lowest quantitative thresholds provided in the rubric for both positive and negative scores (which start at 0.5 M tCO₂e or 500,000 tCO₂e). Furthermore, the emissions increased year-over-year, which would not qualify for positive scores requiring annual declines. Due to the lack of material data points that align with the rubric's quantitative thresholds, no KPIs could be scored.
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to assess Barinthus Biotherapeutics plc against any of the KPIs for the 'Respect for Cultures & Communities' value. The articles discuss unrelated topics such as a fertility doctor's misconduct
1
and ethical principles for medical research
2
, or are unavailable.
3
Safe & Smart Tech
0
No evidence available to assess Barinthus Biotherapeutics plc on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Barinthus Biotherapeutics plc on Zero Waste & Sustainable Products.